GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helixmith Co Ltd (XKRX:084990) » Definitions » COGS-to-Revenue

Helixmith Co (XKRX:084990) COGS-to-Revenue : 0.37 (As of Sep. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Helixmith Co COGS-to-Revenue?

Helixmith Co's Cost of Goods Sold for the three months ended in Sep. 2024 was ₩671 Mil. Its Revenue for the three months ended in Sep. 2024 was ₩1,803 Mil.

Helixmith Co's COGS to Revenue for the three months ended in Sep. 2024 was 0.37.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Helixmith Co's Gross Margin % for the three months ended in Sep. 2024 was 62.77%.


Helixmith Co COGS-to-Revenue Historical Data

The historical data trend for Helixmith Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helixmith Co COGS-to-Revenue Chart

Helixmith Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.99 0.35 0.53 0.85 0.49

Helixmith Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.26 0.50 0.61 0.37

Helixmith Co COGS-to-Revenue Calculation

Helixmith Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2079.771 / 4201.623
=0.49

Helixmith Co's COGS to Revenue for the quarter that ended in Sep. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=671.18 / 1802.995
=0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Helixmith Co  (XKRX:084990) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Helixmith Co's Gross Margin % for the three months ended in Sep. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 671.18 / 1802.995
=62.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Helixmith Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Helixmith Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Helixmith Co Business Description

Traded in Other Exchanges
N/A
Address
1 Gwanak-ro, Gwanak-gu, 5th Floor, Building Number 203, Seoul National University, Seoul, KOR, 08826
Helixmith Co Ltd, formerly ViroMed Co Ltd is active in the healthcare sector in Korea. The company specializes in developing pharmaceutical products for the treatment of diseases related to peripheral artery, coronary artery, cardiovascular system and neuropathy, cancer and allergy. Its suite of products includes protein/deoxyribonucleic acid (DNA)-based biopharmaceuticals, botanical drugs and natural pharmaceuticals.

Helixmith Co Headlines

No Headlines